A5037286347- Parkinson's Disease Mechanisms and Treatments
- Osteoarthritis Treatment and Mechanisms
- Neurological disorders and treatments
- Inflammatory mediators and NSAID effects
- Spine and Intervertebral Disc Pathology
- Botulinum Toxin and Related Neurological Disorders
- Autism Spectrum Disorder Research
- Lysosomal Storage Disorders Research
- Intraperitoneal and Appendiceal Malignancies
- Nuclear Receptors and Signaling
- Attention Deficit Hyperactivity Disorder
- Biochemical and Structural Characterization
- TGF-β signaling in diseases
- Alzheimer's disease research and treatments
- Interactive and Immersive Displays
- Phytochemistry and biological activities of Ficus species
- Tactile and Sensory Interactions
- RNA Interference and Gene Delivery
- Adipokines, Inflammation, and Metabolic Diseases
- Cerebral Palsy and Movement Disorders
- NF-κB Signaling Pathways
- Restless Legs Syndrome Research
- Digestive system and related health
- Cystic Fibrosis Research Advances
- Exercise and Physiological Responses
Leiden University Medical Center
2021-2024
Centre for Human Drug Research
2021-2024
Leiden University
2022
John Wiley & Sons (United States)
2022
Hasselt University
2018
Radboud University Nijmegen
2014-2016
Radboud University Medical Center
2014-2016
Abstract Background α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and considered target for modification. UB‐312 synthetic αSyn peptide conjugated T helper expected induce antibodies specifically against oligomeric fibrillar αSyn, making potential immunotherapeutic synucleopathies. Objective To investigate the safety, tolerability, immunogenicity of vaccination healthy participants determine safe immunologically optimal dose first‐in‐patient...
A mutation in the GBA1 gene is most common genetic risk factor for developing Parkinson's disease. encodes lysosomal enzyme glucosylceramidase beta (glucocerebrosidase, GCase) and mutations decrease activity. LTI-291 an allosteric modulator of GCase, enhancing its These first-in-human studies evaluated safety, tolerability, pharmacokinetics pharmacodynamics single multiple ascending doses healthy volunteers.In dose (SAD) study, 40 volunteers were randomly assigned to (n = 8 per level) or...
Abstract Apomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non‐invasive and user‐friendly alternative. This two‐part clinical study evaluated the safety, tolerability, pharmacokinetics (PK), dose proportionality novel apomorphine hydrochloride solution, as well its relative bioavailability injection sublingual film. In part A study, 12 PD received 2...
ABSTRACT Background Inhalation of apomorphine could be a faster‐acting and more user‐friendly alternative to subcutaneous injection for treating off periods in Parkinson's disease (PD). Objective The aim this study was compare the safety pharmacokinetics inhaled (AZ‐009) with (APO‐go PEN) healthy volunteers (HVs) examine safety, pharmacokinetics, efficacy AZ‐009 patients PD. Methods In part A study, eight HVs received 1 mg 2 randomized crossover manner. subsequent single ascending dose parts...
Increased leucine-rich repeat kinase 2 (LRRK2) activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 inhibitors are in clinical development as potential novel disease-modifying therapeutics. This biomarker characterization study explored within- between-subject variability of multiple pathway biomarkers (total [tLRRK2], phosphorylation the serine 935 (Ser935) residue on [pS935], Rab10 [pRab10], total [tRab10]) different biological sources (whole blood,...
Abstract The validation of objective and easy‐to‐implement biomarkers that can monitor the effects fast‐acting drugs among Parkinson's disease (PD) patients would benefit antiparkinsonian drug development. We developed composite to detect levodopa/carbidopa estimate PD symptom severity. For this development, we trained machine learning algorithms select optimal combination finger tapping task features predict treatment Data were collected during a placebo‐controlled, crossover study with 20...
Movement Disorder Society-Unified Parkinson's Rating Scale Part III (MDS-UPDRS III) is the gold standard for assessing medication effects in patients with disease (PD). However, short and rater-independent measurements would be ideal future trials.To assess ability of 3 different finger tapping tasks to detect levodopa/carbidopa-induced changes over time determine their correlation compare discriminatory power MDS-UPDRS III.This was a randomized, double-blind, crossover study 20 PD receiving...
Parkinson's disease (PD) is a progressive neurodegenerative that affects almost 2% of the population above age 65. To better quantify effects new medications, fast and objective methods are needed. Touchscreen-based tapping tasks simple yet effective tools for quantifying drug on PD-related motor symptoms, especially bradykinesia. However, there no consensus optimal task set-up. The present study compares four in 14 healthy participants. In alternate finger (AFT), occurred with index middle...
<h3>Background and objectives</h3> Pain is the main problem for patients with OA. linked to inflammation, but in OA a subset of suffer from pain without indicating an alternative source pain. NGF inhibition very efficiently blocks during OA, exact unclear. elevated animal models cartilage damage inflammation. TGF-beta released upon damage. We investigated whether could contribute expression joint which signalling route involved. <h3>Materials methods</h3> Murine human chondrocyte cell lines,...
ObjectivesThe combination therapy of CRS and HIPEC should be considered standard care to treat colorectal peritoneal surface malignancy (PSM).Although, there is a near universal standardization regarding CRS, we lack much-needed amongst the IP chemotherapy treatment modalities, including dosing regimen.We rely on pharmacologic evidence supporting standardization.The current regimens can divided into concentration-based BSA-based.Using concept dose intensification, report advantage (PA), i.e....